One institution.
Every position, explained.

Every quarter, institutional investors disclose their equity holdings through SEC 13F filings — but understanding what a single institution is actually doing with its capital requires more than reading raw XML. This report distils one institution's complete disclosed portfolio into clear, structured intelligence — sector allocation, geographic exposure, individual holdings, and what changed quarter-on-quarter and year-on-year.

What this data does — and doesn't — cover.Everything here comes from SEC Form 13F filings, which only institutional investment managers overseeing more than $100 million are required to file, once per quarter. This means the report does not include retail shareholders, company insiders, smaller funds, most non-US investors, or short positions. It is a view of large institutional ownership — an important signal, but not the whole market.

◆

One Institution's Filing

JOHNSON & JOHNSON's complete SEC 13F disclosure — every position, every quarter, structured and visualised for clarity.

◆

What This Report Shows

Portfolio overview, geography, full holdings table, tactical quarterly changes and strategic yearly shifts.

◆

Who It's For

Investors following a specific institution — understanding conviction levels, rotation strategy, and how the portfolio has evolved over time.

This edition:Company Portfolio Focus — a single-institution deep dive into JOHNSON & JOHNSON's holdings and strategy. Two companion editions are available: Industry Focus and Investments Focus.

Institutional Investment Intelligence

Company Portfolio Focus Report

JOHNSON & JOHNSON
Portfolio Deep Dive

Company Portfolio Focus Report

Report DateAugust 08, 2026

Data as ofMarch 31, 2026

Filing PeriodQ1 2026 — 13F Filings

InstitutionJOHNSON & JOHNSON

CIK0000200406

About This Report

This report provides a comprehensive single-institution view of JOHNSON & JOHNSON's disclosed equity portfolio. It covers every position reported through the institution's SEC 13F filing for the period ending March 31, 2026, alongside how the portfolio has changed against both the prior quarter and the prior year — offering a detailed picture of one investor's conviction, rotation, and geographic exposure.

What You Will Find Inside

◆

Portfolio Overview

JOHNSON & JOHNSON's full disclosed position list, key metrics, sector allocation and largest holdings as of Q1 2026.

◆

Holdings by Geography

Where the companies in this portfolio are headquartered — the international footprint of the institution's investments.

◆

Full Holdings Table

Every disclosed equity position ranked by value, with share counts and conviction classification.

◆

Portfolio Change vs Last Quarter

Row-level breakdown of every buy, hold, sell and exit — with share counts and dollar values compared against Q4 2025.

◆

Portfolio Change vs Last Year

Strategic view — sector allocation shift over 12 months, with conviction stability score showing which positions held the full year.

Important Notice to Readers

This report is for informational and educational purposes only and does not constitute investment advice, financial advice, or a recommendation to buy or sell any security.

Data is derived from publicly available filings with the U.S. Securities and Exchange Commission (SEC), specifically Form 13F institutional holdings disclosures. While reasonable efforts have been made to ensure accuracy, no guarantee is provided regarding completeness or reliability of the information presented.

Past institutional holdings do not predict future performance.All investment decisions remain the sole responsibility of the viewer. This document should not be construed as a solicitation or offer to buy or sell any financial instrument.

Coverage note — 13F filers only.This report reflects only holdings disclosed on SEC Form 13F, which is filed exclusively by institutional investment managers holding over $100 million in qualifying U.S. securities. It does not include retail shareholders, company insiders, funds below the $100M threshold, most non-U.S. institutions, or short positions. Figures shown are a partial view of total ownership, filed roughly 45 days after each quarter-end.

© 2025 HoldingsLens · holdingslens.com. For personal use. You're welcome to share this report; redistribution for commercial purposes, resale, or incorporation into other products is prohibited without permission.

How to read this report

Overview & Flows (p.3–5)

Start here for the macro picture — sector capital distribution and investor type flows. The Sankey map shows cross-sector allocation visually.

★ Key Takeaways (p.4)

Read this before the detail pages. It distils the quarter's most actionable signals — what institutions are buying, reducing and holding — with a conviction watchlist.

Portfolio & Changes (p.7–8)

Drill into a specific institution's holdings and what moved quarter-on-quarter. The changes page highlights new entries, exits and meaningful size adjustments.

Quarterly & Yearly Changes (p.8–10)

Cross-reference held stocks against their sector peers. Use the screener to filter the broader universe by country, cap, revenue growth and institutional ownership.

© 2025 HoldingsLens · holdingslens.com — This report is licensed for personal, individual use. You are welcome to share it in full and unmodified. Redistribution for commercial purposes, resale, or incorporation into another product or service is prohibited without written permission.

•Filer ProfileWho the institution is — SIC, sector, activities, website

05Portfolio OverviewProfile, key metrics & holdings snapshot

06Portfolio by GeographyHoldings broken down by company HQ country

07Full Holdings TableEvery disclosed equity position, ranked by value

08Portfolio Change vs Last QuarterTactical — exact share & value deltas

10Portfolio Change vs Last YearStrategic — sector allocation shift & conviction stability

11Most Significant Changes — YoYNew positions, exits, largest increases & reductions by weight

12Go Deeper★ In Development

ⓘ About this report:This is the Company Portfolio Focus edition — a deep dive on one institution's holdings. For sector-wide activity, see the Industry Focus report. For single-stock research, see the Investments report.

Reference details for the institution filing this 13F. Business profile fields are populated when the filer is itself a publicly-listed company; pure investment managers may show fewer fields.

Filer Name

JOHNSON & JOHNSON

CIK

0000200406 ↗

SIC Code

2834 · Pharmaceutical Preparations

Industry

Drug Manufacturers - General

Sector

Healthcare

Own Ticker

JNJ

Fiscal Year End

January 03

Website

—

State of Incorporation

NJ

Employees

141,700

Activities

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Management team — coming in a future edition (requires an additional data source).

JOHNSON & JOHNSON

14 positions · SEC EDGAR ↗

Primary Investment Sector

Healthcare

Latest Reporting

Q1 2026 · March 31, 2026

No. of Investments

14

Total Value

$594.7M

Largest Position

Protagonist Therapeutics, Inc.

Latest Purchase

RLYB — Q1 2026

Latest Closure

LYEL — Q1 2026

Filer CIK

0000200406 ↗

JOHNSON & JOHNSON is an institutional investment manager that files a quarterly SEC Form 13F. This report covers its disclosed US-listed equity portfolio.

Sector Allocation

By investment value · Q1 2026

Healthcare

Sector Activity — Buys vs Sells

Number of positions increased/opened vs reduced/closed, by sector · Q4 2025 → Q1 2026

Positions bought or increasedPositions reduced or closedCounts of trades — unaffected by price moves

73%

Top 3 positions

PTGX, NBTX, RAPP, CVRX, CTNM together account for $551.5M — 92.7% of the portfolio of the total disclosed portfolio.

14

Total positions

Holdings by Industry

Industry	Sector	Investment Value (USD)	% of Portfolio	No. of Holdings
Biotechnology	Healthcare	$547.3M	92.0%	11
Medical - Devices	Healthcare	$47.0M	7.9%	2
Medical - Equipment & Services	Healthcare	$287K	0.0%	1
Total		$594.7M	100.0%	14

ⓘ Scope:Unlike the sector-wide Geography page, this view is scoped to this institution's holdings only — where the companies JOHNSON & JOHNSON invests in are headquartered, not where JOHNSON & JOHNSON itself operates.

Company HQ Country	Region	Value (USD)	% of Portfolio	No. of Holdings
🇺🇸United States	North America	$421.0M	70.8%	13
🇫🇷France	Europe	$173.6M	29.2%	1
Total	2 countries	$594.7M	100.0%	14

ⓘ Country reflects each held company's primary HQ location, not its stock exchange listing. JOHNSON & JOHNSON itself is domiciled in the United States and not counted as a holding.

Ticker	Company	Status	Industry	Sector	Shares Held	Value (USD)	Implied Price	Last Price	First Opened	IPO Date	Website
PTGX	Protagonist Therapeutics, Inc.	—	Biotechnology	Healthcare	2,449,183	$258.1M	$105.40	—	Sep 2021	Aug 2016	www.protagonist-inc.com ↗
NBTX	Nanobiotix S.A.	—	Biotechnology	Healthcare	5,623,816	$173.6M	$30.87	—	Sep 2023	Dec 2020	www.nanobiotix.com ↗
RAPP	Rapport Therapeutics, Inc. Common Stock	—	Biotechnology	Healthcare	1,784,517	$55.8M	$31.29	—	Jun 2024	Jun 2024	www.rapportrx.com ↗
CVRX	CVRx, Inc.	—	Medical - Devices	Healthcare	4,024,861	$38.1M	$9.46	—	Sep 2021	Jun 2021	www.cvrx.com ↗
CTNM	Contineum Therapeutics, Inc.	—	Biotechnology	Healthcare	1,979,173	$25.8M	$13.06	—	Jun 2024	Apr 2024	www.contineum-tx.com ↗
LEGN	Legend Biotech Corporation	—	Biotechnology	Healthcare	814,586	$14.7M	$18.09	—	Sep 2021	Jun 2020	www.legendbiotech.com ↗
XNCR	Xencor, Inc.	—	Biotechnology	Healthcare	748,062	$9.0M	$12.06	—	Dec 2021	Dec 2013	www.xencor.com ↗
PRCT	PROCEPT BioRobotics Corporation	—	Medical - Devices	Healthcare	357,939	$9.0M	$25.01	—	Sep 2021	Sep 2021	www.procept-biorobotics.com ↗
FATE	Fate Therapeutics, Inc.	—	Biotechnology	Healthcare	3,379,064	$4.1M	$1.20	—	Sep 2021	Oct 2013	www.fatetherapeutics.com ↗
NMRA	Neumora Therapeutics, Inc. Common Stock	—	Biotechnology	Healthcare	1,849,445	$3.6M	$1.95	—	Sep 2023	Sep 2023	www.neumoratx.com ↗
RLYB	Rallybio Corporation	★ New	Biotechnology	Healthcare	152,901	$1.4M	$8.97	—	Mar 2026	Jul 2021	www.rallybio.com ↗
VOR	Vor Biopharma Inc.	—	Biotechnology	Healthcare	53,732	$959K	$17.84	—	Dec 2025	Feb 2021	www.vorbio.com ↗
LAB	Standard BioTools Inc.	—	Medical - Equipment & Services	Healthcare	311,967	$287K	$0.92	—	Mar 2024	Feb 2011	www.standardbio.com ↗
ACET	Adicet Bio, Inc.	—	Biotechnology	Healthcare	22,779	$155K	$6.81	—	Dec 2025	Jan 2018	www.adicetbio.com ↗
Showing all 14 disclosed positions.					23,552,025	$594.7M

ⓘ Sorted by value descending. ★ New = position opened this quarter. Implied Price = disclosed value ÷ disclosed shares (not a purchase price; 13F filings do not disclose cost basis). Last Price as of March 31, 2026.

Buy / Increased

1

New or enlarged positions

$1.4M

Hold / Unchanged

13

No share count change

$593.3M

Sell / Reduced

0

Trimmed positions

$0

Exit / Closed

1

Fully closed positions

$1.7M

▲

Buy / Increased Positions

New positions opened or existing holdings increased this quarter

1 positions

Company	Sector	Shares Held (Mar 2026)	Share Change (Δ & %)	Value (USD)
RLYB Rallybio Corporation Biotechnology	Healthcare	152,901	New +152,901 sh	$1.4M

13

Unchanged Positions — Hold

13 securities showed no change in share count between Q4 2025 and Q1 2026. These positions were held steady and include major stakes such as Protagonist Therapeutics, Inc., Nanobiotix S.A., Rapport Therapeutics, Inc. Common Stock. Full details are available in the complete portfolio table. Full details are available in the complete portfolio table.

▼

Sell / Reduced Positions

Existing positions where the number of shares held was trimmed

0 positions

Company	Sector	Shares Held (Mar 2026)	Share Change (Δ & %)	Value (USD)

✕

Exited Positions

Fully closed — zero shares reported in Q1 2026 filing

1 positions

Company	Sector	Shares Held (Dec 2025)	Share Change (Δ & %)	Last Known Value
LYEL Lyell Immunopharma, Inc. Biotechnology	Healthcare	0	Exited -54,887 sh	$1.7M

ⓘ Methodology:Changes are derived by comparing share counts between Q4 2025 and Q1 2026 SEC 13F disclosures. Hold positions are defined as securities where the reported share count is identical across both filings. New positions did not appear in the prior quarter's filing. Net added / removed figures reflect the change in disclosed share count between the two filings; price is not used in these figures. Position values shown in the tables are the values disclosed in the SEC 13F filings. This report does not account for intra-quarter trading activity not reflected in 13F filings.

ⓘ A different lens:The previous page showed exact quarterly trades. This page asks a different question — has the underlying strategy shifted over a full year? Sector weight changes and holding-period stability matter more here than individual transactions.

Sector Allocation — Q1 2025

Sector Allocation — Q1 2026

Healthcare

Sector	Q1 2025 Weight	Q1 2026 Weight	Δ Weight	Value (USD)	Direction
Healthcare	48.6%	100.0%	+51.4%	$594.7M	▲

12-Month Conviction Stability

13 of 14 current positions were held with no change in share count versus a year ago. The remaining positions reflect new entries, exits, and size adjustments — detailed on the preceding pages.

ⓘ Reading this page:All changes are measured Q1 2025 → Q1 2026. Weight (%) is a position’s share of the total market value disclosed in the 13F filing — it shows portfolio composition. Δ Shares shows the actual buying and selling, independent of price movements.

New Positions — Opened this year

0% → new weight

Ticker	Company	Industry	Q1 2025 Weight	Q1 2026 Weight	Δ Weight	Δ Shares	Δ %	Value (USD)	First Quarter
RLYB	Rallybio Corporation	Biotechnology	0.0%	0.2%	+0.2%	+152,901	New	$1.4M	Mar 2026
VOR	Vor Biopharma Inc.	Biotechnology	0.0%	0.2%	+0.2%	+53,732	New	$959K	Dec 2025
ACET	Adicet Bio, Inc.	Biotechnology	0.0%	0.0%	+0.0%	+22,779	New	$155K	Dec 2025

Largest Increases — By portfolio weight shift

Existing positions grown significantly

Ticker	Company	Industry	Q1 2025 Weight	Q1 2026 Weight	Δ Weight	Δ Shares	Δ %	Value (USD)	Shares Now
PTGX	Protagonist Therapeutics, Inc.	Biotechnology	19.9%	43.4%	+23.5%	0	0.0%	$258.1M	2,449,183
NBTX	Nanobiotix S.A.	Biotechnology	3.4%	29.2%	+25.8%	0	0.0%	$173.6M	5,623,816
RAPP	Rapport Therapeutics, Inc. Common Stock	Biotechnology	4.2%	9.4%	+5.2%	-713,534	-28.6%	$55.8M	1,784,517
CTNM	Contineum Therapeutics, Inc.	Biotechnology	2.3%	4.3%	+2.0%	0	0.0%	$25.8M	1,979,173
XNCR	Xencor, Inc.	Biotechnology	1.3%	1.5%	+0.2%	0	0.0%	$9.0M	748,062
FATE	Fate Therapeutics, Inc.	Biotechnology	0.4%	0.7%	+0.2%	0	0.0%	$4.1M	3,379,064
NMRA	Neumora Therapeutics, Inc. Common Stock	Biotechnology	0.3%	0.6%	+0.3%	0	0.0%	$3.6M	1,849,445

Largest Reductions — By portfolio weight shift

Existing positions trimmed significantly

Ticker	Company	Industry	Q1 2025 Weight	Q1 2026 Weight	Δ Weight	Δ Shares	Δ %	Value (USD)	Shares Now
CVRX	CVRx, Inc.	Medical - Devices	8.4%	6.4%	-2.0%	-78,569	-1.9%	$38.1M	4,024,861
LEGN	Legend Biotech Corporation	Biotechnology	4.6%	2.5%	-2.2%	0	0.0%	$14.7M	814,586
PRCT	PROCEPT BioRobotics Corporation	Medical - Devices	3.5%	1.5%	-2.0%	0	0.0%	$9.0M	357,939

Exits — Positions fully closed this year

Weight → 0%

Ticker	Company	Industry	Q1 2025 Weight	Q1 2026 Weight	Δ Weight	Shares Divested	Δ %	Value (USD)	Last Quarter Held

ⓘ Weight shifts reflect each position's % of total portfolio value. AAPL's −16.85pp reduction is the most significant single-position change — driven primarily by a large share count reduction, not price decline. AXP's weight increased despite unchanged share count, reflecting strong price appreciation relative to the overall portfolio. All data is illustrative dummy data.

★ This report is a snapshot

You just saw 1 institution. The platform tracks thousands.

This report covered JOHNSON & JOHNSON — 28 positions, one quarter, one year of history. The platform is under active development, and will extend this same depth of analysis to every 13F filer.

1→1000s

Institutions tracked

In Progress

Platform status

Qtrly

Current refresh

Compare Any Two Institutions

Side-by-side portfolio comparison — overlap, divergence, and relative conviction between any two 13F filers.

Position Change Alerts

Get notified the moment this institution opens, closes, or materially resizes a position — don't wait for the next filing.

Full Filing History

This report shows 1 year. The platform has every quarterly filing back to when the institution started disclosing.

Raw Data Export

Download structured datasets for your own models — CSV, JSON, or direct API access.

We're still building this

HoldingsLens is under active development. Your input directly shapes what we prioritise next.

Learn more →

Have thoughts on this report? Share feedback →

JOHNSON & JOHNSONPortfolio Deep Dive

Company Portfolio Focus Report

Portfolio Overview

Holdings by Geography

Full Holdings Table

Portfolio Change vs Last Quarter

Portfolio Change vs Last Year

Unchanged Positions — Hold

JOHNSON & JOHNSON
Portfolio Deep Dive